For the quarter ending 2026-03-31, CTKB made $44,135K in revenue. -$18,866K in net income. Net profit margin of -42.75%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue, net | 44,135 | 62,141 | 52,293 | 45,602 |
| Service | - | - | - | 6,814 |
| Product | - | - | - | 14,921 |
| Total cost of sales | 22,881 | 29,256 | 24,742 | 21,735 |
| Gross profit | 21,254 | 32,885 | 27,551 | 23,867 |
| Research and development | 9,604 | 8,961 | 8,956 | 8,826 |
| Sales and marketing | 11,646 | 13,131 | 11,666 | 12,134 |
| General and administrative | 18,467 | 16,386 | 16,121 | 13,531 |
| Total operating expenses | 39,717 | 38,478 | 36,743 | 34,491 |
| Loss from operations | -18,463 | -5,593 | -9,192 | -10,624 |
| Interest expense | 262 | -725 | 494 | 414 |
| Interest income | 787 | 580 | 573 | 555 |
| Other income, net | 565 | 257 | 1,344 | 3,708 |
| Total other income, net | 1,090 | 1,562 | 1,423 | 3,849 |
| Loss before income taxes | -17,373 | -4,031 | -7,769 | -6,775 |
| Provision for income taxes | 1,493 | 40,045 | -2,291 | -1,192 |
| Net loss | - | -44,076* | -5,478 | - |
| Less net loss allocated to noncontrolling interests | - | 0* | - | - |
| Net loss | -18,866 | - | - | -5,583 |
| Net loss attributable to common stockholders, diluted | - | -44,076 | - | - |
| Net loss, basic | -18,866 | - | -5,478 | -5,583 |
| Basic Average Shares | 128,704,934 | 128,162,122 | 127,547,859 | 126,934,294 |
| Diluted Average Shares | 128,704,934 | 128,162,122 | 127,547,859 | 126,934,294 |
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)